Pro-/antiinflammatory dysregulation in early psychosis: Results from a 1-year follow-Up study
Resumen: Background: Previous studies indicated a systemic deregulation of the pro-/antiinflammatory balance in subjects after 6 months of a first psychotic episode. This disruption was reexamined 12 months after diagnosis to identify potential risk/ protective factors and associations with symptom severity.
Methods: Eighty-five subjects were followed during 12 months and the determination of the same pro-/antiinflammatory mediators was carried out in plasma and peripheral blood mononuclear cells. Multivariate logistic regression analyses were used to identify risk/protective factors. Multiple linear regression models were performed to detect the change of each biological marker during follow-up in relation to clinical characteristics and confounding factors.
Results: This study suggests a more severe systemic pro-/antiinflammatory deregulation than in earlier pathological stages in first psychotic episode, because not only were intracellular components of the inflammatory response increased but also the majority of soluble elements. Nitrite plasma levels and cyclooxygenase-2 expression in peripheral blood mononuclear cells are reliable potential risk factors and 15d-prostaglandin-J2 plasma levels a protection biomarker. An interesting relationship exists between antipsychotic dose and the levels of prostaglandin-E2 (inverse) and 15d-prostaglandin-J2 (direct). An inverse relationship between the Global Assessment of Functioning scale and lipid peroxidation is also present.
Conclusions: Summing up, pro-/antiinflammatory mediators can be used as risk/protection biomarkers. The inverse association between oxidative/nitrosative damage and the Global Assessment of Functioning scale, and the possibility that one of the targets of antipsychotics could be the restoration of the pro-/antiinflammatory balance support the use of antiinflammatory drugs as coadjuvant to antipsychotics.

Idioma: Inglés
DOI: 10.1093/ijnp/pyu037
Año: 2015
Publicado en: International Journal of Neuropsychopharmacology 18, 2 (2015), 1-10
ISSN: 1461-1457

Factor impacto JCR: 4.333 (2015)
Categ. JCR: CLINICAL NEUROLOGY rank: 35 / 192 = 0.182 (2015) - Q1 - T1
Categ. JCR: PSYCHIATRY rank: 28 / 142 = 0.197 (2015) - Q1 - T1
Categ. JCR: PHARMACOLOGY & PHARMACY rank: 39 / 255 = 0.153 (2015) - Q1 - T1
Categ. JCR: NEUROSCIENCES rank: 62 / 256 = 0.242 (2015) - Q1 - T1

Factor impacto SCIMAGO:

Financiación: info:eu-repo/grantAgreement/ES/MINECO-ISCIII/CIBERSAM
Tipo y forma: Article (Published version)
Área (Departamento): Area Psiquiatría (Dpto. Medicina, Psiqu. y Derm.)
Área (Departamento): Área Medic.Prevent.Salud Públ. (Dpto. Microb.Med.Pr.,Sal.Públ.)

Creative Commons You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes.

Exportado de SIDERAL (2019-03-13-11:52:19)

Este artículo se encuentra en las siguientes colecciones:

 Record created 2016-07-25, last modified 2019-03-13

Versión publicada:
Rate this document:

Rate this document:
(Not yet reviewed)